The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease
Open accessAbstract
Background and aims: The clinical course of inflammatory bowel disease is characterised by a succession of relapses and remissions. The aim of our study was to assess whether the predictive value of faecal calprotectin—a non-invasive marker of intestinal inflammation—for clinical relapse is different in ulcerative colitis (UC) and Crohn’s disease (CD). Methods: Seventy nine consecutive patients with a diagnosis of clinically quiescent inflammatory bowel disease (38 CD and 41 UC) were followed for 12 months, undergoing regular clinical evaluations and blood tests. A single stool sample was collected at the beginning of the study from each patient and the calprotectin concentration was assessed by a commercially available enzyme linked immunoassay. Results: In CD, median calprotectin values were 220.1 μg/g (95% confidence interval (CI) 21.7–418.5) in those patients who relapsed during follow up, and 220.5 μg/g (95% CI 53–388) in non-relapsing patients (p = 0.395). In UC, median calprotectin values were 220.6 μg/g (95% CI 86–355.2) and 67 μg/g (95% CI 15–119) in relapsing and non-relapsing patients, respectively (p<0.0001). The multivariate Cox (proportional hazard) regression model, after adjustment for possible confounding variables, showed a twofold and 14-fold increase in the relapse risk, respectively, in those patients with CD and UC in clinical remission who had a faecal calprotectin concentration higher than 150 μg/g. Conclusions: Faecal calprotectin proved to be an even stronger predictor of clinical relapse in UC than in CD, which makes the test a promising non-invasive tool for monitoring and optimising therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rachmilewitz, D. (1989) · BMJ · doi:10.1136/bmj.298.6666.82 · Cited by 1,039
Tibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K., & Bjarnason, I. (2000) · Gastroenterology · doi:10.1053/gast.2000.8523 · Cited by 759
Clinical, biological, and endoscopic picture of attacks of Crohn's disease
Modigliani, R., Mary, J.-Y., Simon, J.-F., Cortot, A., Soule, J.-C., Gendre, J.-P., & Rene, E. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90002-i · Cited by 699
Microscopic activity in ulcerative colitis: what does it mean?
Riley, S. A., Mani, V, Goodman, M. J., Dutt, S., & Herd, M. E. (1991) · Gut · doi:10.1136/gut.32.2.174 · Cited by 564
Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
Best, W. R., Becktel, J. M., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90384-6 · Cited by 562
A simple method for assessing intestinal inflammation in Crohn's disease
Tibble, J., Teahon, K., Thjodleifsson, B., Roseth, A., Sigthorsson, G., Bridger, S., Foster, R., Sherwood, R., Fagerhol, M., & Bjarnason, I. (2000) · Gut · doi:10.1136/gut.47.4.506 · Cited by 492
Cellier, C., Sahmoud, T., Froguel, E., Adenis, A., Belaiche, J., Bretagne, J. F., Florent, C., Bouvry, M., Mary, J. Y., & Modigliani, R. (1994) · Gut · doi:10.1136/gut.35.2.231 · Cited by 430
A. G. Røseth, P. N. S. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529950172835 · Cited by 422
Røseth, A. G., Aadland, E., Jahnsen, J., & Raknerud, N. (1997) · Digestion · doi:10.1159/000201441 · Cited by 365
Role of faecal calprotectin as non-invasive marker of intestinal inflammation
Costa, F., Mumolo, M. G., Bellini, M., Romano, M. R., Ceccarelli, L., Arpe, P., Sterpi, C., Marchi, S., & Maltinti, G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00381-5 · Cited by 289
Self-citationEndoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
Landi, B., Anh, T. N., Cortot, A., Soule, J. C., Rene, E., Gendre, J. P., Bories, P., See, A., Metman, E. H., Florent, C., et al. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91725-j · Cited by 261
Limburg, P. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01987-0 · Cited by 171
Non-invasive investigation of inflammatory bowel disease
Tibble, J. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i4.460 · Cited by 167
Clinical Remission in Crohn’s Disease – Assessment Using Faecal 111 ln Granulocyte Excretion
Saverymuttu, S. H. (2009) · Digestion · doi:10.1159/000199277 · Cited by 66
Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders
Røseth, A. G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00375-x · Cited by 47
Cited by
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006) · Gut · doi:10.1136/gut.2005.069476 · Cited by 952
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
DʼHaens, G., Ferrante, M., Vermeire, S., Baert, F., Noman, M., Moortgat, L., Geens, P., Iwens, D., Aerden, I., Van Assche, G., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22917 · Cited by 816
van Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010) · BMJ · doi:10.1136/bmj.c3369 · Cited by 714
Metadata
- Authors
- Costa, F., Mumolo, M. G., Ceccarelli, L., Bellini, M., Romano, M. R., Sterpi, C., Ricchiuti, A., Marchi, S., & Bottai, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-02-11
- Volume
- 54
- Issue
- 3
- Pages
- 364-368
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2160240762
- Cited by
- 550
- References
- 15
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.